Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
MoleculeMind logo — AI-Driven Biologics Discovery, Design and Development

MoleculeMind

AI-Driven Biologics Discovery, Design and Development

Founded 2022 China Beijing, China 29 employees Series A Total: $400.00M Biotechnology, Pharmaceutical

General Information

Company Name MoleculeMind
Founded Year 2022
Location China Beijing, China
Employees 29
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Usage Based, Tiered Pricing
Social

BounceWatch is an independent company data service, not affiliated with MoleculeMind. To contact MoleculeMind, visit moleculemind.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MoleculeMind compare?

A PDF of MoleculeMind and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MoleculeMind soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 26, 2026

MoleculeMind is attending the AIDDD summit at Boston Marriott Copley Place from October 27-29.

Growth Metrics Oct 16, 2026

MoleculeMind's MMDesign platform achieved 100% success across all 6 tested GPCRs and a 94.7% success rate across 19 campaigns.

New Partnership Oct 14, 2026

MoleculeMind joins AIDDD 2026 as a Diamond Partner.

MoleculeMind a competitor of yours? Have our desk watch it

AI Insight

Bounce Watch AI
6 days ago

MoleculeMind has significantly expanded its product offering with the launch of MOS™, an AI engine for biologic drug discovery, while simultaneously showcasing robust technological validation through its MMDesign platform's 100% success rate across key targets. This strong product development and proven efficacy are coupled with increased market visibility and strategic partnerships, evidenced by its Diamond Partner status at the AIDDD 2026 summit. These coordinated moves underscore a strategic push towards commercialization and solidifying its position in the AI-driven biologics space.

Signal Types
Product Launch Traction Partnership Event Participation
Strategic Labels
Product Expansion Market Penetration Technology Validation
Next Move: Commercialization
·
Impact: 9/10
·
Ideal For: Biotech VCs — Series B / Growth Stage

About MoleculeMind

MoleculeMind, founded in 2022, is making strides in the Biotechnology and Pharmaceutical industries with its AI-Driven Protein Discovery and Design. The company specializes in revolutionizing protein design and optimization through its flagship platform, MoleculeOS. By leveraging cutting-edge AI algorithms, MoleculeMind empowers professionals across various fields, including chemistry, materials science, synthetic biology, and agriculture, to efficiently identify and generate a wide range of proteins such as peptides, antibodies, enzymes, and small proteins.

The platform's broad application capabilities are transforming the landscape of protein-related R&D, marking a significant advancement in innovation and commercial progress for the industries it serves. In its recent financing round, MoleculeMind secured a CNY200.00M Series A investment on 01 September 2024, with backing from notable investors such as Shenzhen Capital Group, Shangjiu Investment, Sense Capital, and Guangzhou Xie Nuo Investment Group. This injection of capital underscores confidence in the company's vision and potential for significant market impact.

Business keywords: AI Protein Design, Protein Optimization, Macromolecule Optimization, Deep Learning for Proteins, Peptide Research, Antibody Design, Enzyme Optimization, Synthetic Biology Solutions, Material Science Proteins, Industrial Protein Applications, Agricultural Protein Design, AI Algorithms for Proteins, Biopharmaceutical Innovation, Protein-Driven R&D, Commercial Protein Innovation

Services & Products

AI-Powered MoleculeOS Platform
Precision Structural Optimization
Biological Engineering

Target Customers

Pharmaceutical Companies Biotech Researchers Healthcare Innovators Industrial Production Firms

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $100.00M 14
Capital Partners Oriental Fortune Capital Zhongping Capital
Capital Partners, Oriental Fortune Capital +12
01 Jun 2026
Series A CNY200.00M 4
Shenzhen Capital Group Shangjiu Investment Sense Capital
Shenzhen Capital Group, Shangjiu Investment +2
01 Sep 2024
Early VC CNY100.00M 3
Lenovo Capital
Lenovo Capital, Sequoia +1
01 Feb 2023
Angel Undisclosed 1
Baidu Ventures
Baidu Ventures
01 Apr 2022
Spinout Undisclosed 2
The University of Chicago
The University of Chicago, Toyota Technological Institute at Chicago
01 Jan 2022

MoleculeMind Alternatives & Competitors

View All Alternatives
MoleculeMind vs
Biomatter
Biomatter Lithuania

Previously impossible enzymes for your visionary products

Seed
36 employees
Biopharma, Biotechnology
MoleculeMind vs
BigHat Biosciences
BigHat Biosciences United States

Designing transformative therapeutics by integrating frontier AI with autonomous generation of gold-...

Series B
98 employees
Biotechnology, Pharmaceutical
MoleculeMind vs
Basecamp Research
Basecamp Research United Kingdom

Basecamp Research trains frontier AI models for therapeutic design.

Series C
76 employees
AI, Biotechnology
Compare MoleculeMind vs Basecamp Research
View all alternatives

FAQ About MoleculeMind

AI-Driven Biologics Discovery, Design and Development
MoleculeMind was founded in 2022.
MoleculeMind is headquartered in Beijing, China.
MoleculeMind operates in Biotechnology and Pharmaceutical. Its work centres on AI Protein Design, Protein Optimization, Macromolecule Optimization and Deep Learning for Proteins. Its customers include Pharmaceutical Companies, Biotech Researchers and Healthcare Innovators.
MoleculeMind has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Tiered Pricing.
MoleculeMind has approximately 29 employees.
MoleculeMind has completed 5 funding rounds, raising a total of $400.00M. The latest funding stage is Series A.
MoleculeMind offers: AI-Powered MoleculeOS Platform, Precision Structural Optimization, Biological Engineering.
Top alternatives and competitors to MoleculeMind include Biomatter, BigHat Biosciences, Basecamp Research, Avenue Biosciences, iktos. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MoleculeMind and Biomatter are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MoleculeMind, https://www.bouncewatch.com/company/moleculemind, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout